Top Midday Stories: Trump Touts Talks With New Iranian Regime, Renews Threats; Sysco to Acquire Jetro for $29.1 Billion

All three major US stock indexes were up in late-morning trading Monday after President Donald Trump said in a Truth Social post that the US is working with the new regime in Iran to end the military conflict.

In addition to his comments on talks with the new regime, President Trump said in his post that the US will blow up all of Iran's electricity-generating plants, oil wells, Kharg Island, and possibly its desalination plants if the Strait of Hormuz isn't opened immediately.

In company news, Sysco (SYY) has agreed to acquire Jetro Restaurant Depot in a cash-and-stock deal valued at $29.1 billion, the companies said Monday. Under the deal terms, Jetro shareholders will receive $21.6 billion in cash proceeds and 91.5 million Sysco shares. The deal is expected to close in fiscal Q3. Sysco shares were down 11.8% around midday.

Viridian Therapeutics (VRDN) said Monday its phase 3 trial of elegrobart in patients with active thyroid eye disease met its primary endpoint of a statistically significant proptosis responder rate, or PRR, for the dosing regimen of every four weeks. The four-week dosing regimen achieved a 54% PRR at week 24, while the group with a dosage of every eight weeks achieved a 63% PRR. Elegrobart was also well tolerated in both dose groups, the company said. Viridian shares were down nearly 32%.

Boston Scientific (BSX) said Saturday that a global clinical trial demonstrated its Ekos blood clot device, combined with anticoagulants, outperformed standard treatments for patients with intermediate-risk pulmonary embolisms. Study participants reduced associated mortality and severe respiratory failure events by 61% within seven days compared to using blood thinners alone, the company said. Boston Scientific shares were down 9.2%.

United Therapeutics (UTHR) said Monday a pivotal study of nebulized Tyvaso in idiopathic pulmonary fibrosis met the primary efficacy endpoint, increased forced vital capacity by 130.1 mL at 52 weeks and reducing the risk of clinical worsening compared with a placebo. United Therapeutics shares were up 13%.

Price: 72.15, Change: -9.65, Percent Change: -11.79